UK Markets open in 2 hrs 9 mins

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
21.67+1.87 (+9.44%)
At close: 04:00PM EDT

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees762

Key executives

NameTitlePayExercisedYear born
Mr. Thomas LingelbachChairman of the Management Board, Pres & CEO798.28kN/A1963
Mr. Franck Grimaud MBADirector Gen., Chief Bus. Officer & Member of Management Board500.62kN/A1967
Mr. Frederic JacototVP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board392.93kN/A1965
Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer & Member of the Management Board547.15kN/A1971
Mr. Peter BuhlerCFO & Management Board MemberN/AN/A1971
Mr. Perry CelentanoInterim Chief Operating OfficerN/AN/AN/A
Mr. Joshua Drumm Ph.D.VP of Investor RelationsN/AN/AN/A
Ms. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsN/AN/AN/A
Mr. Gerald StrohmaierVP of Human ResourceN/AN/AN/A
Mr. Christian TaucherHead of Global Medical AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Corporate governance

Valneva SE’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.